Demonising Justin Gatlin
13th September 2015
Six anti-doping rule violations (ADRVs) were recorded by Anti-Doping Switzerland during 2019, 0.3% of the 2,017 tests it conducted in the year. The body’s Annual Report (PDF below) reveals it spent CHF949,103 (€893,780) on testing during 2019, which means that on average (as the cost of blood and urine tests differs), each test cost Anti-Doping Switzerland CHF470.5 (€440), and each ADRV CHF158,183 (€148,917).
During the year, Anti-Doping Switzerland referred eleven possible ADRVs to the Swiss Olympic Committee’s Disciplinary Chamber for Doping Cases. This was four more than during 2018, but only six resulted in ADRVs, the same number as during 2018. Two cases involved the use of testosterone; one involved selective androgen receptor modulators (SARMS); one involved a hormonal and metabolic modulator; one involved cocaine and another cannabis.
During the year, Anti-Doping Switzerland approved 35 Therapeutic Use Exemptions (TUEs) from 99 applications, however only one was rejected. This was because two thirds of the applications were unnecessary, as they involved substances that are not prohibited in sport. TUEs allow athletes to use substances prohibited in sport providing that they can prove they have a medical need.
Seventeen warnings regarding ‘whereabouts’ information were issued by Anti-Doping Switzerland during the year, however none of these progressed to a third warning. Under the World Anti-Doping Code, athletes who are part of a registered testing pool (RTP) must file information stating where they will be available to be tested for one hour in every 24, three months in advance. Three failures to be present at the stated location is considered to be an ADRV.
USADA announced today that Cole Walsh, of Glendale, Ariz., an athlete in the sport of...